The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Glucagon-Like Peptide-1 Receptor Imaging for Localization of Insulinomas
Open accessAbstract
CONTEXT: The surgical removal of insulinomas is hampered by difficulties to localize it using conventional radiological procedures. Recently these tumors were shown to exhibit a very high density of glucagon-like peptide-1 receptors (GLP-1R) in vitro that may be used as specific targets for in vivo receptor radiolabeling. OBJECTIVE: The objective of the study was to test the 111In-labeled GLP-1R agonist 111In-DOTA-exendin-4 in localizing insulinomas using single photon emission computed tomography in combination with computed tomography images. DESIGN: This was a prospective open-label investigation. SETTING: The study was conducted at three tertiary referral centers in Switzerland. PATIENTS: Patients included six consecutive patients with proven clinical and biochemical endogenous hyperinsulinemic hypoglycemia. INTERVENTION: (111)In-DOTA-exendin-4 was administered iv at a dose of about 90 MBq (30 microg peptide) over 5 min. Whole-body planar images of the abdomen were performed at 20 min, 4 h, 23 h, 96 h, and up to 168 h after injection. After surgical removal of the insulinomas, GLP-1R expression was assessed in the tumor tissue in vitro by GLP-1R autoradiography. MAIN OUTCOME MEASURE: The detection rate of insulinomas was measured. RESULTS: In all six cases, the GLP-1R scans successfully detected the insulinomas identified using conventional methods in four cases. By using a gamma-probe intraoperatively, GLP-1R detection permitted a successful surgical removal of the tumors in all patients, diagnosed histopathologically as five pancreatic and one extrapancreatic insulinomas. In vitro GLP-1R autoradiography showed a high density of GLP-1R in all tested insulinomas. CONCLUSION: In vivo GLP-1R imaging is an innovative, noninvasive diagnostic approach that successfully localizes small insulinomas pre- and intraoperatively and that may in the future affect the strategy of insulinoma localization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Gastroenteropancreatic neuroendocrine tumours
Modlin, I. M., Oberg, K., Chung, D. C., Jensen, R. T., de Herder, W. W., Thakker, R. V., Caplin, M., Delle Fave, G., Kaltsas, G. A., Krenning, E. P., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70410-2 · Cited by 1,748
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
Reubi, J. C. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0007 · Cited by 1,131
Self-citationReubi, J., Waser, B., Schaer, J.-C., & Laissue, J. A. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100541 · Cited by 657
Self-citationReubi, J. C., & Waser, B. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1184-3 · Cited by 592
Self-citationInternational Union of Pharmacology. XXXV. The Glucagon Receptor Family
Mayo, K. E., Miller, L. J., Bataille, D., Dalle, S., Göke, B., Thorens, B., & Drucker, D. J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.6 · Cited by 506
Service, F. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504273321707 · Cited by 503
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 2×
“GLP-1R expression was evaluated in vitro by GLP-1R autoradiography as previously reported using (125)I-GLP-1 (7– 36)amide (74 Bq/mmol; Anawa, Wangen, Switzerland) as radioligand in sections of patients’ tumor samples (21).”
BackgroundMethodSelf-citationKwekkeboom, D. J., Bakker, W. H., Kam, B. L., Teunissen, J. J. M., Kooij, P. P. M., de Herder, W. W., Feelders, R. A., van Eijck, C. H. J., de Jong, M., Srinivasan, A., et al. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-1050-8 · Cited by 424
Placzkowski, K. A., Vella, A., Thompson, G. B., Grant, C. S., Reading, C. C., Charboneau, J. W., Andrews, J. C., Lloyd, R. V., & Service, F. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2031 · Cited by 360
Well-Differentiated Pancreatic Tumor/Carcinoma: Insulinoma
de Herder, W. W., Niederle, B., Scoazec, J.-Y., Pauwels, S., Klöppel, G., Falconi, M., Kwekkeboom, D. J., Öberg, K., Eriksson, B., Wiedenmann, B., et al. (2006) · Neuroendocrinology · doi:10.1159/000098010 · Cited by 295
Grant, C. S. (2005) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2005.05.008 · Cited by 281
Wild, D., Béhé, M. P., WICKI, A. N., Storch, D., Waser, B., Gotthardt, M., Keil, B. R., Christofori, G., Reubi, J. C., & Mäcke, H. R. (2006) · PubMed · Cited by 195
Self-citationGlucagon-like Peptide 1–Receptor Scans to Localize Occult Insulinomas
Wild, D., Mäcke, H., Christ, E., Gloor, B., & Reubi, J. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0802045 · Cited by 192
Self-citationGuettier, J.-M., Kam, A., Chang, R., Skarulis, M. C., Cochran, C., Alexander, H. R., Libutti, S. K., Pingpank, J. F., & Gorden, P. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1986 · Cited by 178
Kauhanen, S. P., Seppänen, M., Minn, H. R. I., Gullichsen, R., Salonen, A., Alanen, K. A., Parkkola, R. K., Solin, O. H., Bergman, J. R., Sane, T., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1479 · Cited by 169
Multimodality preoperative imaging of pancreatic insulinomas
McAuley, G., Delaney, H., Colville, J., Lyburn, I. D., Worsley, D. F., Govender, P., & Torreggiani, W. C. (2005) · Clinical Radiology · doi:10.1016/j.crad.2005.06.005 · Cited by 118
A new technique for in vivo imaging of specific GLP-1 binding sites: First results in small rodents
Gotthardt, M., Lalyko, G., van Eerd, J. E. M., Keil, B. R., Schurrat, T., Hower, M., Laverman, P., Behr, T. M., Boerman, O. C., Göke, B., et al. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.07.005 · Cited by 101
Glucagon and Glucagon-Like Peptide Receptors as Drug Targets
Estall, J. L., & Drucker, D. J. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206776873671 · Cited by 96
Endoscopic Ultrasonography for the Preoperative Localization of Insulinomas
Pitre, J., Soubrane, O., Palazzo, L., & Chapuis, Y. (1996) · Pancreas · doi:10.1097/00006676-199607000-00007 · Cited by 95
Wiesli, P., Brändle, M., Schmid, C., Krähenbühl, L., Furrer, J., Keller, U., Spinas, G. A., & Pfammatter, T. (2004) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.0000140638.55375.1e · Cited by 93
Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data
Gallwitz, B. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01196.x · Cited by 68
Imaging and localization of pancreatic insulinomas
Chatziioannou, A. N., Kehagias, D., Mourikis, D., Antoniou, A., Limouris, G. S., Kaponis, A. I., Kavatzas, N., TSELENI, S., & Vlachos, L. (2001) · Clinical Imaging · doi:10.1016/s0899-7071(01)00290-x · Cited by 54
What should be done in an operating room when an insulinoma cannot be found?
Rostambeigi, N., & Thompson, G. B. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03527.x · Cited by 53
Cited by
Falconi, M., Eriksson, B., Kaltsas, G., Bartsch, D. K., Capdevila, J., Caplin, M., Kos-Kudla, B., Kwekkeboom, D., Rindi, G., Klöppel, G., et al. (2016) · Neuroendocrinology · doi:10.1159/000443171 · Cited by 1,362
Jensen, R. T., Cadiot, G., Brandi, M. L., de Herder, W. W., Kaltsas, G., Komminoth, P., Scoazec, J.-Y., Salazar, R., Sauvanet, A., & Kianmanesh, R. (2012) · Neuroendocrinology · doi:10.1159/000335591 · Cited by 622
Radiolabeled Peptides: Valuable Tools for the Detection and Treatment of Cancer
Fani, M., Maecke, H. R., & Okarvi, S. M. (2012) · Theranostics · doi:10.7150/thno.4024 · Cited by 333
Self-citationPeptide Receptor Radionuclide Therapy: An Overview
Dash, A., Chakraborty, S., Pillai, M. R. A., & Knapp, F. F. (. (2015) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2014.1741 · Cited by 128
Antwi, K., Fani, M., Heye, T., Nicolas, G., Rottenburger, C., Kaul, F., Merkle, E., Zech, C. J., Boll, D., Vogt, D. R., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4101-5 · Cited by 124
Self-citation
Metadata
- Authors
- Christ, E., Wild, D., Forrer, F., Brändle, M., Sahli, R., Clerici, T., Gloor, B., Martius, F., Maecke, H., & Reubi, J. C.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2009-11-01
- Volume
- 94
- Issue
- 11
- Pages
- 4398-4405
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2061192940
- Cited by
- 268
- References
- 24
- FWCI
- 11.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.